Optimizing gastrointestinal tolerability is a critical aspect of drug development to minimize discomfort and improve patient adherence, especially when considering escalating doses
In the early stage of the disease, this response may be protective
[1] [2] Marketed under the brand names Mounjaro (for diabetes) and Zepbound (for weight management as an adjunct to reduced-calorie diet and increased physical activity), tirzepatide represents the first dual incretin receptor agonist available in clinical practice
Heres the way by which tirzepatide operates: Control of blood sugar: Like GLP-1, tirzepatide helps stimulate insulin release in response to meals, thereby enhancing glucose control through better body responses to sugar in the blood after eating
Millar said patient demand for the drug to treat a severe form of fatty liver disease - which became eligible for coverage in 2025 - is a small but growing part of the business
Generally speaking, once you have completely stopped breastfeeding, there is no need to wait an extended period before starting tirzepatide
